June 26, 2020 / 10:19 PM / 9 days ago

BRIEF-Gilead Terminates License Agreement For Long-Acting Injectable HIV Investigational Product

June 26 (Reuters) - DURECT Corp:

* GILEAD TERMINATES LICENSE AGREEMENT FOR LONG-ACTING INJECTABLE HIV INVESTIGATIONAL PRODUCT

* DURECT CORP - DURECT ANTICIPATES RECOGNIZING REMAINING DEFERRED REVENUE OF APPROXIMATELY $23.1 MILLION IN Q2 OF 2020

* DURECT CORP - DURECT EXPECTS TO RECOGNIZE NET INCOME FOR Q2 OF 2020 Source text for Eikon: Further company coverage: (Reuters.Briefs@thomsonreuters.com)

0 : 0
  • narrow-browser-and-phone
  • medium-browser-and-portrait-tablet
  • landscape-tablet
  • medium-wide-browser
  • wide-browser-and-larger
  • medium-browser-and-landscape-tablet
  • medium-wide-browser-and-larger
  • above-phone
  • portrait-tablet-and-above
  • above-portrait-tablet
  • landscape-tablet-and-above
  • landscape-tablet-and-medium-wide-browser
  • portrait-tablet-and-below
  • landscape-tablet-and-below